As previously reported, Oppenheimer analyst Jay Olson initiated coverage of Coherus Oncology (CHRS) with an Outperform rating and $10 price target citing upcoming clinical readouts in 2026 across multiple cancers for lead anti-CCR8 antibody tagmokitug combined with in-licensed, commercial PD-1 backbone Loqtorzi. Additionally, the firm thinks casdozokitug, Coherus’ “only-in-class” anti-IL-27 antibody, represents “a high-potential early-stage opportunity,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Oncology initiated with an Outperform at Oppenheimer
- Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug
- Coherus Biosciences: Strategic Positioning and Growth Potential with Loqtorzi Leading the Charge
- Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial